ArticleJACC. Advances2026
Impact of Downregulated Inflammation via the IL6R Asp358Ala Variant on Atrial Fibrillation Recurrence Following Ablation.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundElevated interleukin (IL)-6 levels are associated with the development of atrial fibrillation (AF). Whether downregulation of IL-6 mediated inflammation reduces AF recurrence following ablation is uncertain.
objectivesUsing a common variant in the IL-6 receptor gene, IL6R Asp358Ala, as a genetic proxy for IL-6 receptor blockade, we evaluated the effect of impaired IL-6 signaling on AF recurrence following ablation.
methodsWe identified patients undergoing AF ablation with genomic data in the All of Us Research database. Patients were stratified based on the presence of the IL6R Asp358Ala allele. The primary outcome was AF recurrence, defined as a composite of repeat AF ablation, cardioversion, or new class I/III antiarrhythmic drug, following a 3-month blanking period after ablation.
resultsOf the 1,540 patients undergoing AF ablation, 707 patients carried 1 copy of the Asp358Ala variant and 226 carried 2 copies. At a median follow-up of 1,317 days, the AF recurrence rate was 14.2 per 100 patient-years for carriers of Asp358Ala as compared to 15.9 for noncarriers (adjusted HR: 0.93, 95% CI: 0.79-1.10). No difference in recurrence was observed when using an additive model (2 vs 1 vs no variant allele), suggesting no dose-response with the variant. In subgroup analysis of patients with heart failure (n = 312), there was a potential beneficial effect of Asp358Ala on recurrence (adjusted HR: 0.72, 95% CI: 0.52-1.00; interaction P = 0.049).
conclusionsTargeted IL-6 inhibition may have little impact on long-term AF recurrence in the general AF population undergoing ablation, although there may be potential benefit in heart failure patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.